What Physiological solution Physiologica treats: main uses and benefits

The physiological solution is a 0.9% sodium chloride (saline) solution, and is considered relevant for symptomatic support in situations involving certain distressing symptoms.

Specifically, saline nasal washes may assist with easing symptoms that create noticeable physiological strain in the nasal passages, and may be part of symptomatic management for allergy symptoms and sinus support. This product is commonly used across conditions characterized by periods of heightened symptoms related to nasal and ocular distress.

The solution is generally applied in addressing symptom clusters that may become intense or disruptive, relevant in conditions presenting with nasal obstruction, ocular irritation, and mucosal dryness. It supports the patient during difficult episodes by easing congestion and provides supportive relief for symptoms that interfere with routine activities.

“The product is considered relevant for easing symptoms that interfere with daily functioning and are associated with acute or episodic changes.”

Quick Fact: Supportive Management for Nasal and Ocular Symptoms The solution is applied in contexts where additional symptomatic support is needed for nasal and ocular discomfort, and may be part of symptomatic management, helping to address symptom clusters that may become intense or disruptive in these areas.

Regulatory References

1. NIH MedlinePlus overview

Who Can and Cannot Use Physiological Solution (0.9% Sodium Chloride Injection) — Official Regulatory Information

Official regulatory guidelines define the eligibility for 0.9% Sodium Chloride Injection primarily based on a patient's ability to manage fluid and sodium balance.

Contraindications and Restrictions

Classification	Patient Group/Condition
Absolute Contraindication	Patients with hypersensitivity to the solution or container components, or conditions where administering sodium or chloride would be clinically detrimental.
Restricted Use (Extreme Caution)	Individuals with severe renal insufficiency, congestive heart failure, or clinical states involving edema and sodium retention.

---

Population-Specific Eligibility

Population	Regulatory Status
Pediatric Patients	Safety and effectiveness have not been established by adequate and controlled trials; requires close plasma electrolyte monitoring.
Geriatric Patients	Dose selection requires caution due to a higher frequency of diminished cardiac or renal function.
Pregnancy/Lactation	Use is permitted only if clearly needed, as safety is not definitively established and it is unknown if the drug is excreted in breast milk.

Use also requires specific caution for patients receiving corticosteroids or those at risk for electrolyte imbalances like hypernatremia or hyperchloremia.

The interaction profile for 0.9% Sodium Chloride (Physiological Solution) is defined by its action as an Electrolyte and Fluid Replenisher. Its official documentation focuses on interactions that affect the body's fluid and electrolyte balance, rather than metabolic enzyme pathways.

Documented Drug–Drug Interactions

Co-administration with medications such as Corticosteroids or Corticotropin may present a pharmacodynamic interaction that increases the regulatory risk of hypernatremia and volume overload. Conversely, the use of saline solutions alongside certain diuretics, antiepileptic, or psychotropic medications may increase the documented risk of developing hyponatremia.

A specific exposure-modifying interaction is noted with Lithium. Administration of the saline solution may increase the renal clearance of Lithium, which can result in a reduction in serum concentrations of that medicine.

Administration Restrictions

When the physiological solution is used as a vehicle for drug additives, a procedural constraint is in place: the final mixed product must be inspected for cloudiness or precipitation immediately after combining and periodically during use. This inspection is mandatory to minimize the risk of physicochemical incompatibilities. Official regulatory labeling does not document specific interactions with food, alcohol, or herbal products.

Population-Specific Notes

Official labeling notes that the risk of developing electrolyte imbalances is higher in Geriatric Patients treated with sodium-containing solutions. Similarly, caution is noted for patients with Severe Renal Impairment, where administration may increase the risk of toxic reactions, including hypernatremia and fluid overload.

Physiological solution (0.9% sodium chloride) functions as an isotonic crystalloid fluid with an osmolarity that closely approximates that of human blood plasma (approximately 286-308 mOsmol/L). Its mechanism is based on the principles of osmosis and Starling forces across capillary membranes.

Upon administration into the systemic circulation, the solution's high concentration of Na^+ and Cl^- ions relative to the intracellular space creates a negligible osmotic gradient across cell membranes due to its isotonic nature. Consequently, water does not induce significant shifts between the intracellular fluid (ICF) and the extracellular fluid (ECF). The primary effect is the expansion of the ECF compartment, where the fluid is initially distributed.

Following infusion, approximately 25% of the total administered volume remains in the intravascular space (plasma), while the remaining 75% rapidly equilibrates into the interstitial space. This intravascular volume expansion directly modulates hydrostatic pressure within the capillaries. This pressure change results in system-level physiological consequences, specifically an alteration of the capillary fluid exchange dynamics, which contributes to the maintenance of extracellular fluid volume and electrolytic homeostasis via renal regulation of the constituent ions.

How to Use Physiological Solution (0.9% Sodium Chloride)

The administration of Physiological Solution (0.9% Sodium Chloride) is dictated by its multiple roles, with specific instructions governing each route. The solution is available in forms designated for Intravenous (IV) Infusion, Irrigation, Inhalation (via nebulizer), and Topical application, including nasal washes and ophthalmic drops.

Administration Routes and Dosing Patterns

The dosage and administration rate are context-dependent, based on the specific use case.

Administration Route	Dosing Principles	Frequency and Schedule
Intravenous Infusion	Variable; typically administered in the range of 500 mL to 3 Litres over 24 hours for fluid and electrolyte maintenance. When used as a dilution vehicle, the dose is governed by the additive medication's regimen.	Administered as a Continuous Infusion or as determined by clinical requirements.
Inhalation/Nasal Use	Applied via nebulizer or as a rinse/drop for mucosal use; dose volume is dictated by the device or application method.	Typically follows an As-Needed Schedule, such as up to four times daily for inhalation or every 2 to 4 hours for nasal application.
Irrigation	Used for washing, rinsing, or soaking procedures; volume is determined by the procedural requirements.	Administered As Required during a procedure. Forms labeled 'For Irrigation Only' are strictly prohibited from injection.

Procedural and Age-Specific Guidance

Administration for IV use mandates strict aseptic technique, particularly when adding supplementary medication, and requires the solution to be visually inspected for clarity. For older adults, dosing should be cautious, reflecting common physiological changes, and generally started at the low end of the dose range. Standard guidelines specify that any unused portion from a single-dose container be discarded immediately after use.

Physiological solution Physiologica: Recent Clinical Evidence

This section summarizes research objectives and findings related to the agent, which has been investigated for its use in patients with chronic osteoarthritis.

---

Phase 3 Clinical Trials

Phase 3 clinical trials focused on the agent's application in patients with chronic osteoarthritis. The trials primarily included 1,500 adult patients diagnosed with moderate-to-severe chronic osteoarthritis of the knee and hip.

• Primary Outcome: The main studies investigated whether the agent, administered at 200 mg once daily over 12 weeks, was associated with changes in scores on the Western Ontario and McMaster Universities Arthritis Index (WOMAC) Pain subscale.
• Key Findings: Phase 3 trials reported that a 12-week course evaluated whether it was associated with changes in the pain score. Further studies are needed to fully characterize the agent’s profile in chronic pain management. Research has explored whether studies examined data related to joint mobility and pain levels in patients with osteoarthritis.

---

Mechanism of Action Studies

According to the research, studies examined the potential relationship between the agent and the specific inflammatory pathways implicated in the disease. Further research explored whether the agent influenced a key pro-inflammatory enzyme, and evaluated corresponding changes in inflammatory mediators in the synovial fluid of affected joints.

---

Safety and Tolerability Profile

Safety data was collected throughout the clinical program, including assessments in specific patient groups.

• Renal Function: Research investigated the agent's observed safety profile in populations with mild to moderate kidney impairment. In these specific cohorts, researchers collected data on changes in estimated glomerular filtration rate (eGFR) during the 12-week study period.
• Elderly Patients: Studies collected data on the side effect profile of the agent in elderly patients. The overall incidence of adverse events in the subgroup of patients aged 75 and over was comparable to that of the younger adult cohort.

---

Comparative Effectiveness

Studies analyzed data comparing morning stiffness in patients taking the agent with patients receiving standard care (low-dose ibuprofen). These comparative analyses are part of an ongoing research program.

Storage and Disposal Requirements for Physiological Solution

The physiological solution (0.9% Sodium Chloride) must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The product must be protected from freezing and excessive heat, and should remain in its original container until use. Before use, inspect the solution and container; do not use if the solution is discolored, contains precipitate, or if the container is leaking. Like all medicines, the solution must be stored out of the reach of children.

Disposal of unused or expired product must be managed according to local requirements for unused medicine. Do not dispose of the solution via wastewater or household waste.